000285818 001__ 285818
000285818 005__ 20260402150927.0
000285818 0247_ $$2doi$$a10.1001/jamapsychiatry.2025.4390
000285818 0247_ $$2pmid$$apmid:41637064
000285818 0247_ $$2pmc$$apmc:PMC12874077
000285818 0247_ $$2ISSN$$a2168-622X
000285818 0247_ $$2ISSN$$a0003-990X
000285818 0247_ $$2ISSN$$a0375-8532
000285818 0247_ $$2ISSN$$a1538-3636
000285818 0247_ $$2ISSN$$a2168-6238
000285818 0247_ $$2ISSN$$a2330-9636
000285818 037__ $$aDZNE-2026-00354
000285818 041__ $$aEnglish
000285818 082__ $$a610
000285818 1001_ $$aSalahuddin, Nurul Husna$$b0
000285818 245__ $$aPsychological and Psychosocial Interventions for People With Schizophrenia and Co-Occurring Substance Use Disorders: A Systematic Review and Meta-Analysis.
000285818 260__ $$aChicago, Ill.$$bAMA$$c2026
000285818 3367_ $$2DRIVER$$aarticle
000285818 3367_ $$2DataCite$$aOutput Types/Journal article
000285818 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1775135151_16505
000285818 3367_ $$2BibTeX$$aARTICLE
000285818 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000285818 3367_ $$00$$2EndNote$$aJournal Article
000285818 520__ $$aSubstance use disorder (SUD) is commonly found in individuals with schizophrenia, with a high co-occurrence rate of approximately 41.7%. Despite this high prevalence, people with both schizophrenia and SUD are frequently excluded from clinical trials and systematic reviews; this special group is particularly challenging to treat and imposes a significant economic burden on health care systems.To evaluate the efficacy, acceptability, and tolerability of psychological and psychosocial interventions in patients with schizophrenia and co-occurring SUD.The Cochrane Schizophrenia Group registry was searched up to January 13, 2025. Data analysis was performed from March to April 2025.Randomized clinical trials (RCTs) examining psychological and psychosocial interventions compared with control groups in adults with schizophrenia and concomitant SUD were identified. No restrictions were applied regarding the type of substance used, including alcohol, cannabis, nicotine, and stimulants, such as amphetamines.A systematic review and random-effect pairwise meta-analyses were conducted to estimate standardized mean differences (SMD) with 95% confidence intervals and were reported following Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) reporting guidelines. Confidence in the estimate was assessed with the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach.The primary outcomes were overall symptoms and substance use reduction measured by validated scales at posttreatment.A total of 35 RCTs were included (4136 participants), with 29 trials involving 3831 participants contributing to pairwise meta-analyses comparing psychological and psychosocial interventions with control conditions. Among the 3748 participants with reported sex, 951 (25.4%) were female, and mean (range) age was 37.2 (20.6-57.5) years. A very small effect favoring the intervention group was observed in reducing overall symptoms (SMD, -0.11; 95% CI, -0.27 to 0.05; 13 trials; low confidence in the estimate), mainly driven by nicotine studies. No difference was found between intervention and control groups in reducing all types of substance use (SMD, -0.01; 95% CI, -0.21 to 0.18; 8 trials; moderate confidence). When considered separately, alcohol, cannabis, amphetamines, and other stimulants showed similar no-effect results, while nicotine use indicated a small effect.The findings of this systematic review and meta-analysis suggest that current psychological and psychosocial interventions provide limited benefit in reducing symptoms and no effect in reducing substance use in individuals with schizophrenia and SUD compared to control conditions, with the exception of nicotine use, highlighting the urgent need to develop more effective treatment strategies.
000285818 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x0
000285818 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000285818 650_2 $$2MeSH$$aHumans
000285818 650_2 $$2MeSH$$aSubstance-Related Disorders: therapy
000285818 650_2 $$2MeSH$$aSubstance-Related Disorders: epidemiology
000285818 650_2 $$2MeSH$$aSubstance-Related Disorders: complications
000285818 650_2 $$2MeSH$$aSchizophrenia: therapy
000285818 650_2 $$2MeSH$$aSchizophrenia: epidemiology
000285818 650_2 $$2MeSH$$aPsychosocial Intervention: methods
000285818 650_2 $$2MeSH$$aComorbidity
000285818 650_2 $$2MeSH$$aPsychotherapy: methods
000285818 650_2 $$2MeSH$$aDiagnosis, Dual (Psychiatry)
000285818 650_2 $$2MeSH$$aRandomized Controlled Trials as Topic
000285818 7001_ $$aHerlitzius, Emilia$$b1
000285818 7001_ $$aSchütz, Alexandra$$b2
000285818 7001_ $$aSiafis, Spyridon$$b3
000285818 7001_ $$0P:(DE-2719)2811122$$aPriller, Josef$$b4$$udzne
000285818 7001_ $$aLeucht, Stefan$$b5
000285818 7001_ $$aBighelli, Irene$$b6
000285818 773__ $$0PERI:(DE-600)2698864-1$$a10.1001/jamapsychiatry.2025.4390$$gVol. 83, no. 4, p. 353 -$$n4$$p353$$tJAMA psychiatry$$v83$$x2168-622X$$y2026
000285818 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2811122$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b4$$kDZNE
000285818 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x0
000285818 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bJAMA PSYCHIAT : 2022$$d2024-12-13
000285818 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-13
000285818 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-13
000285818 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-13
000285818 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2024-12-13
000285818 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2024-12-13
000285818 915__ $$0StatID:(DE-HGF)1180$$2StatID$$aDBCoverage$$bCurrent Contents - Social and Behavioral Sciences$$d2024-12-13
000285818 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2024-12-13
000285818 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2024-12-13
000285818 915__ $$0StatID:(DE-HGF)0130$$2StatID$$aDBCoverage$$bSocial Sciences Citation Index$$d2024-12-13
000285818 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2024-12-13
000285818 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2024-12-13
000285818 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-13
000285818 915__ $$0StatID:(DE-HGF)9925$$2StatID$$aIF >= 25$$bJAMA PSYCHIAT : 2022$$d2024-12-13
000285818 9201_ $$0I:(DE-2719)5000007$$kAG Priller$$lTranslational Neuropsychiatry$$x0
000285818 980__ $$ajournal
000285818 980__ $$aEDITORS
000285818 980__ $$aVDBINPRINT
000285818 980__ $$aI:(DE-2719)5000007
000285818 980__ $$aUNRESTRICTED